Dl-Threonine
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
DL-Threonine: No Repurposing Prediction Generated — Hold Pending Data Resolution
One-Sentence Summary
DL-Threonine is a racemic amino acid compound (equal mixture of L- and D-threonine enantiomers), with no current SAHPRA registration or confirmed approved indication on record. The TxGNN model was unable to generate any repurposing predictions for this compound, as no DrugBank identifier was resolved and no original regulatory indications were available as input. Without these foundational data elements, evidence-level classification and a clinical rationale cannot be established at this time.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available |
| Predicted New Indication | No prediction generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | Not assignable — pipeline inputs missing |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
The TxGNN repurposing pipeline requires two foundational inputs to function:
- A valid DrugBank ID — used to locate the drug node within the knowledge graph (KG) and execute both KG-based and deep-learning (DL) predictions.
- At least one approved indication — used to contextualise the drug’s position within the drug–disease network.
For DL-Threonine, neither input was successfully resolved. No DrugBank ID was returned in this Evidence Pack, and the original indications list is empty. As a result, the TxGNN model had no entry point into the knowledge graph and no predictions were produced.
From general pharmacological knowledge, DL-Threonine is the racemic form of the essential amino acid threonine. The biologically active enantiomer, L-Threonine (DrugBank: DB00156), is involved in protein biosynthesis, intestinal mucosal integrity, hepatic lipid metabolism, and immune function. It is primarily used as a nutritional supplement or enteral feeding component rather than a conventional pharmaceutical. Whether the DL-racemic form warrants a separate repurposing evaluation — distinct from L-Threonine — is itself a question that requires pharmacological clarification before proceeding.
South Africa Market Information
No SAHPRA-registered products were identified for DL-Threonine. This compound has no licensed pharmaceutical registrations in South Africa at this time.
If DL-Threonine is intended to be evaluated as a nutritional supplement or functional food ingredient rather than a registered medicine, a different regulatory pathway (e.g., Section 21 authorisation or Complementary Medicine framework) may be applicable.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN repurposing evaluation for DL-Threonine cannot proceed because the two critical pipeline inputs — DrugBank ID and approved indication — are both absent. There is no prediction score, no evidence trail, and no mechanism-of-action data to evaluate. Issuing a repurposing recommendation under these conditions would not be clinically meaningful.
To proceed, the following is needed:
- Resolve the DrugBank ID: Determine whether DL-Threonine maps to DB00156 (L-Threonine) or requires a distinct identifier. If the racemic form is not separately listed in DrugBank, consider evaluating L-Threonine as the primary entity.
- Establish the original approved indication: Retrieve product labelling from SAHPRA, TFDA, or an international reference authority (EMA, FDA, TGA) to confirm the registered therapeutic use.
- Re-run the TxGNN pipeline: Once DrugBank mapping and original indication are confirmed, re-submit for KG and DL predictions.
- Clarify the clinical entity: Confirm whether the target of this evaluation is DL-Threonine (racemic), L-Threonine (pure enantiomer), or a combination product containing threonine as an active component.
- Obtain safety data: Download and parse the approved PI document to populate warnings, contraindications, and drug interaction fields before any safety-based decision can be made.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.